Addressing the Multibillion-Dollar Injectable Drug Markets with Oral Formulations December 2019
Safe Harbor Certain statements contained in this material are forward-looking statements. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities, and others, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission. which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward-looking statements. Oramed undertakes no obligation to update or revise any forward-looking statements. 2
Oramed Snapshot ▪ Proprietary oral protein delivery platform ▪ Diabetes first - initially targeting the lucrative insulin market ▪ Robust pipeline leveraging IP portfolio for additional significant market opportunities ▪ Strong financial position over $33.5M in cash and investments, no debt 1 ▪ Experienced management team backed by world-class scientific experts ▪ Multiple value-creation events for 2020 ▪ NASDAQ/TASE: ORMP 3 1 As of August 31, 2019
Proprietary Technology for Oral Drug Delivery Proteins and Peptides do Not Survive Oramed Technology Protects Drug Integrity and the Digestive System Increases Absorption Harsh pH pH shield Sensitive enteric coating protects Stomach acidity cleaves capsule contents before entering and shreds protein small intestine Protease attack Protease protection Proteases attack and Protease inhibitors protect the break down proteins active agent Absorption enhancement Absorption barrier Assists the permeation of Therapeutic proteins fail proteins/peptides across intestinal to be absorbed via the membrane and into bloodstream intestinal wall (barrier) 4
Multiple Clinical-Stage Programs Phase I Phase II Phase III ORMD-0801 (Oral Insulin) Type 2 Diabetes ORMD-0801 (Oral Insulin) Type 1 Diabetes ORMD-0901 (Oral GLP-1) Type 2 Diabetes Exploratory Studies Leptin (T1DM – PD: glucose and glycogen reduction; PK) NASH (T2DM – fibrosis reduction) 5
Diabetes: Millions of diabetics inject insulin today and wish for oral dosage
1 in 11 Adults on the Planet Have Diabetes 1 in 8 WORLD healthcare In 2017 diabetes 415 M expenditure reached People live with US $ 727 billion spent on diabetes diabetes PREVALENCE 9.09% 2017 expected increase: +204 every 6 SECONDS 2045 MILLION 1 adult dies from diabetes 4M deaths in 2017 7 http://www.diabetesatlas.org/key-messages.html
ORMD-0801: Oral Insulin
ORMD-0801 - Flagship Product for Oral Treatment of Diabetes No Serious >650 ~6000 Adverse study subjects human doses Events * *Serious drug-related adverse events 9
The Drawbacks of Injected Insulin vs. the Advantages of Oral Insulin ENDOGENOUS INSULIN produced by the pancreas and delivered to the body via the liver To systemic circulation stomach Injected Insulin introduced directly to the bloodstream, with only a fraction of it reaching the liver. This can cause excess sugar to be stored in fat and muscle which often results in weight gain and may liver also cause hypoglycemia. Oral insulin , like natural insulin, is delivered first to the liver, resulting in: ✓ Better blood glucose control portal vein ✓ Reduced hypoglycemia ✓ Reduced hyperglycemia small intestine ✓ Reduced weight gain (neutral) 10
ORMD-0801 for Type 1 & Type 2 Diabetes Diabetes inhibits the production of sufficient insulin and causes elevated levels of glucose in the blood TYPE 1 Diabetes TYPE 2 Diabetes ▪ T1DM is autoimmune: The body destroys its ▪ T2DM is metabolic: The body becomes insulin own insulin-producing (beta) cells, leaving resistant. Injections may be used to make up for patients completely dependent on external the pancreas ’ s inability to create sufficient insulin sources insulin to keep blood sugar at normal levels ▪ 10% of diabetics have T1DM: Up to 37 million ▪ 371 million people worldwide need treatment people worldwide have T1DM ▪ Projected Market: $59 billion by 2025 ▪ Projected Market: $13 billion by 2023 11
ORMD-0801 for Type 1 Diabetes (T1DM) Potentially eliminating the need for insulin before each meal T1DM patients are treated with various types Oramed seeks to replace the mealtime of insulin replacement therapy (bolus) insulin doses ▪ Easier use and reduced systemic exposure ▪ Long-acting insulin (basal) helps maintain stable insulin levels during fasting periods ▪ Potentially reducing multiple daily injections ▪ Rapid-acting insulin (bolus) prior to each ▪ Tighter regulation and control of blood meal to stabilize blood sugar sugar levels by directly targeting liver ▪ Administration is via injection or pump glucose, due to portal administration 12
Phase IIa FDA Study Consistent and Accumulative Effect of ORMD-0801 for Treating Type 1 Diabetes Blood glucose levels lower day and night compared to control group Reduction in FBG Oral Insulin Reduces Exogenous Insulin 10.00 Requirements Delta Placebo vs ORMD Basal or Bolus Insulin (units) 2 Delta Placebo vs ORMD Delta -10.00 Basal -3 FPG (mg/dl) Insulin Decreased -30.00 -8 Delta ✓ use of rapid-acting insulin Bolus -50.00 -13 Insulin ✓ levels of post-meal glucose -70.00 -18 Delta Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 FPG ✓ levels of daytime glucose days of times a day T1DM 7 25 3 (at mealtime) patients treatment Safe and Well Tolerated Primary Evaluate change in exogenous insulin Endpoint: requirements in T1DM patients 13
Completed: 180 Patient FDA Phase 2 Study for Type 2 Diabetes 33 US sites 180 patients 28 day treatment 1 Dose (nightly) 14
FDA Phase 2 FDA Study Achieved Every Primary Endpoint with No Drug Related Serious Adverse Events Nighttime CGM Glucose Nighttime CGM Glucose Nighttime CGM Glucose Mean % change Mean mg/dl change Median mg/dl change Placebo Change from run-in – 80% trim Placebo 13.70 Placebo 12.38 8.48 ORMD-0801 2.01* ORMD-0801 1.66* ORMD-0801 -0.35* Last 2 days Last 2 days Last 2 days * Indicates Statistically Significant Difference versus Placebo (p-Value<0.05) 15
FDA Phase 2 FDA Study Exploratory Endpoints: CGM Parameters Fasting Daytime 24 Hours 5AM to 7AM 6AM to 10PM Mean Change from Run-in Period Placebo P-value=<0.0001* Glucose (mg/dl) 15.95 Placebo Placebo P-value=<0.0001* 13.26 P-value=0.0010* ORMD-0801 11.88 P-value=0.0010* ORMD-0801 ORMD-0801 0.88* P-value=<0.0001* P-value=<0.0001* -0.32* -0.41* * Indicates p-Value<0.05 16
Completed: 233 Patient FDA Phase 2b (Cohort A) Study 34 US sites* 233 Patients* 90 Day treatment 3 Doses * 36 Sites: 2 Sites (significant treatment by center interaction) = 34 • 269 subjects received primary treatment and had baseline A1c (included in ITT) • 233 subjects included in primary analysis • 2 sites (36 subjects) were excluded due to significant treatment by center interaction 17
FDA Phase 2b: 90-day HbA1c Study Cohort A Cohort B ▪ Size: ~250 T2DM subjects ▪ Size: ~75 T2DM subjects ▪ Dose Regimen : ▪ Dose : 16 mg → 24 mg → 32 mg/dose 8 mg X 1 & 8 mg x 2 - Dose Regimen: - 16 mg X 1 & 16 mg X 2 ▪ X1 (evening) – 32 mg/day - ▪ Results Expected in 1Q20 ▪ X2 (evening + before breakfast) – 64 mg/day ▪ X3 (evening + before breakfast + before lunch) – 96 mg/day 18
Phase 2b: Cohort A Primary 01 ▪ Mean change in HbA1c from baseline to Week 12 Endpoint ▪ Safety (AEs, hypoglycemic) Secondary 02 ▪ Fasting Plasma Glucose (FPG) + CGM Endpoints ▪ Mixed-Meal Tolerance Test (MMTT) ▪ Weight 19
Recommend
More recommend
